Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem | Zendy

Wonhee So | Zendy; Jared L. Crandon | Zendy; Yukihiro Hamada | Zendy; David P. Nicolau | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem

Author(s) -

Wonhee So,

Jared L. Crandon,

Yukihiro Hamada,

David P. Nicolau

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv370

Subject(s) - amikacin , meropenem , pharmacodynamics , microbiology and biotechnology , klebsiella pneumoniae , pharmacology , pseudomonas aeruginosa , antibacterial agent , medicine , antibiotics , chemistry , pharmacokinetics , biology , bacteria , antibiotic resistance , biochemistry , escherichia coli , genetics , gene

While Amikacin Inhale (BAY41-6551), an integrated drug-device combination under development, achieves an estimated amikacin epithelial lining fluid (ELF) concentration of ∼ 5000 mg/L, its target site pharmacodynamics are unknown. We evaluated the pharmacodynamics of ELF exposure of inhaled amikacin ± meropenem.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research